ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Nephrology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

29,516Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 30

$1.32M Total Retail Price of All Prescriptions

Rank: 1 out of 30

759 Patients Receiving at Least One Drug in Part D
90% Patients 65 Years and Older
76% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Rhode Island
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

7% of this provider’s 759 patients filled at least one prescription for a schedule two drug, compared to an average of 0%.

Schedule Three
Controlled Substances

4% of this provider’s 759 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 18%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

39 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
WARFARIN SODIUM 1,706 1,656 65 1 7
FUROSEMIDE 1,423 1,308 160 2 2
METOPROLOL TARTRATE 1,069 984 164 3 4
TRAZODONE HCL 976 885 157 4 15
LISINOPRIL 875 788 160 5 3
AMLODIPINE BESYLATE 791 745 132 6 1
LEVOTHYROXINE SODIUM 783 717 121 7 11
SERTRALINE HCL 732 664 107 8 22
SIMVASTATIN 715 628 129 9 8
OMEPRAZOLE 700 621 136 10 9
ATORVASTATIN CALCIUM 553 482 109 11 10
QUETIAPINE FUMARATE 412 377 51 A 12 33
MIRTAZAPINE 409 371 68 13 34
GABAPENTIN 385 288 61 14 25
PRAVASTATIN SODIUM 357 343 61 15 26
DONEPEZIL HCL 354 349* 62 16 35
DIOVAN 343 338* 31 17 14
HYDROCHLOROTHIAZIDE 337 332* 59 18 12
METOPROLOL SUCCINATE 334 292 49 19 20
POLYETHYLENE GLYCOL 3350 305 257 79 20 41
NAMENDA 299 299 28 21 43
CYMBALTA 276 228 22 22 47
CITALOPRAM HBR 275 222 46 23 32
ESCITALOPRAM OXALATE 256 256 33 24 48
TRAMADOL HCL 254 217 52 25 40
POTASSIUM CHLORIDE 250 223 27 26 39
LANTUS 249 218 40 27 50
LOSARTAN POTASSIUM 237 232* 42 28 5
CLOPIDOGREL 236 204 49 29 38
IPRATROPIUM-ALBUTEROL 227 211 63 30 51
ATENOLOL 225 220* 39 31 18
TAMSULOSIN HCL 215 199 40 32 27
METFORMIN HCL 197 179 40 33 42
RANITIDINE HCL 180 129 28 34 49
CARVEDILOL 175 157 36 35 28
MELOXICAM 173 139 28 36 60
GLIPIZIDE 167 149 35 37 45
LEVETIRACETAM 165 128 28 38 61
DIGOX 164 150 30 39 62
SPIRIVA 154 125 33 40 64
PREDNISONE 152 104 46 41 16
ABILIFY 152 126 15 A 41 65
ALENDRONATE SODIUM 148 143* 26 43 68
HYDROCODONE-ACETAMINOPHEN 146 106 30 S3 44 36
CIPROFLOXACIN HCL 141 120 72 45 70
VENLAFAXINE HCL ER 140 120 16 46 71
DOXAZOSIN MESYLATE 139 128 24 47 6
ALPRAZOLAM 138 116 33 B 48 53
ALBUTEROL SULFATE 132 111 39 49 74
KLOR-CON M20 128 100 34 50 56
NEXIUM 122 58 12 51 58
DIVALPROEX SODIUM 121 94 22 52 75
RISPERIDONE 121 116* 27 A 52 75
ADVAIR DISKUS 118 95 27 54 77
ENULOSE 118 61 26 54 77
ALLOPURINOL 114 109* 22 56 13
LEVOFLOXACIN 112 107* 57 57 80
LIDODERM 111 106* 22 58 81
PROAIR HFA 101 80 32 59 66
ISOSORBIDE MONONITRATE ER 98 93* 22 60 54
MUPIROCIN* 98 76 38 60 82
LOVASTATIN 97 97 18 62 83
OXYBUTYNIN CHLORIDE ER 94 89* 20 63 84
FENOFIBRATE* 90 <11 <11 64 63
FINASTERIDE 89 89 16 65 85
LATANOPROST 88 88 13 66 86
NOVOLOG 87 82* 12 67 87
ENOXAPARIN SODIUM 85 <11 <11 68 88
SULFAMETHOXAZOLE-TRIMETHOPRIM 83 78* 46 69 31
LOSARTAN-HYDROCHLOROTHIAZIDE 81 <11 <11 70 90
DILTIAZEM 24HR CD 80 80 14 71 91
OXYCODONE HCL 79 35 22 S2 72 92
TIMOLOL MALEATE 78 <11 <11 73 94
CRESTOR 77 58 14 74 95
VENLAFAXINE HCL 77 55 15 74 95
ZETIA 75 <11 <11 76 59
AMOX TR-POTASSIUM CLAVULANATE 74 69* 38 77 97
OLANZAPINE 74 69* 11 A 77 97
FAMOTIDINE* 73 50 14 79 100
FOSINOPRIL SODIUM 73 <11 <11 79 100
BACLOFEN 72 <11 <11 81 102
PAROXETINE HCL 71 49 16 82 103
LORAZEPAM 71 66* 22 B 82 69
GLIPIZIDE ER 70 65* 12 84 104
VERAPAMIL ER 70 <11 <11 84 104
FENOFIBRATE* 70 56 16 84 63
EXFORGE 69 69 11 87 106
OXYCODONE-ACETAMINOPHEN 68 63* 11 S2 88 107
HYDRALAZINE HCL 67 62* 15 89 29
KLOR-CON M10 67 62* 13 89 108
SPIRONOLACTONE 66 53 13 91 24
BUSPIRONE HCL 65 35 11 92 109
CHLORHEXIDINE GLUCONATE 65 34 18 92 109
AZITHROMYCIN 64 59* 44 94 111
CEPHALEXIN 64 59* 39 94 111
CARBIDOPA-LEVODOPA 63 <11 <11 96 113
CLOZAPINE 63 <11 <11 A 96 113
NITROFURANTOIN MONO-MACRO 61 56* 29 98 115
DILTIAZEM HCL 61 <11 <11 98 115
GLIMEPIRIDE 61 <11 <11 98 115
PHENYTOIN 60 <11 <11 101 118
QUINAPRIL HCL 60 55* 11 101 37
PANTOPRAZOLE SODIUM 59 54* 21 103 46
RESTASIS 59 <11 <11 103 119
HUMALOG 59 54* 14 103 119
FLUTICASONE PROPIONATE 57 43 19 106 123
SYMBICORT 57 52* 16 106 123
VENTOLIN HFA 56 36 21 108 127
MONTELUKAST SODIUM 53 <11 <11 109 132
BRIMONIDINE TARTRATE 52 52 11 110 134
FLOVENT HFA 52 <11 <11 110 134
TRIAMCINOLONE ACETONIDE 52 47* 23 110 134
DOXYCYCLINE HYCLATE 51 46* 22 113 138
DILTIAZEM ER 51 <11 <11 113 138
ENALAPRIL MALEATE 51 <11 <11 113 138
CLONAZEPAM 51 29 11 B 113 138
LAMOTRIGINE 51 <11 <11 113 138
FLUOXETINE HCL 50 39 13 118 67
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 6, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.